Full Year 2025 Thor Medical ASA Earnings Call Transcript
Key Points
- Thor Medical ASA (STU:8NN) is on track with the completion of its Alpha One facility, which is expected to start production in Q3 2026.
- The company has secured an order backlog of NOK850 million, indicating strong demand for its products.
- Thor Medical ASA has strategic agreements with key suppliers, ensuring a stable supply of raw materials.
- The company is fully funded with a cash reserve of NOK180.6 million and additional financial facilities, allowing it to reach cash positive status by 2027.
- Thor Medical ASA has attracted high-caliber talent, enhancing its operational capabilities and execution potential.
- The company reported a negative EBITDA of NOK25.7 million and a loss before taxes of NOK30.5 million for the period.
- There is uncertainty in the market due to Sanofi's decision to deprioritize certain assets, which could impact market dynamics.
- Thor Medical ASA's reliance on a few key customers could pose a risk if any agreements fall through.
- The company is not providing specific guidance on Capex expenditure, creating uncertainty about future financial commitments.
- The market for thorium-based isotopes is still emerging, and the timeline for the approval of relevant drugs remains uncertain, potentially affecting future revenues.
Good morning and a warm welcome to all joining us today for our presentation of Thor Medical's results for the second half and full year of 2025.
My name is Matthias Nielsen. I'm the head of corporate communications and corporate affairs here at the For Medical.
And it's a pleasure for me to be here today, welcoming you for the very first time. I'm looking forward to interacting with you in the time ahead.
So just a couple of practicalities.
This presentation contains forward-looking statements, and the complete disclaimer is available in the presentation material that was published earlier today.
And we have set aside some time for questions after the presentation, so we will open the floor for questions in the room. And for those of you following us through webcast, please put in your questions now.
And with me today I have my colleagues Jasper Kurth, CEO of Thor Medical, and also Brede Ellingsæter Chief Financial and operating officer at Thor Medical. So
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
